Biotech IV Monitor

AMGN — Amgen Inc.

$239.2B market cap · 7 upcoming readouts tracked

Clinical trial readout dates for Amgen Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts75 Phase 3
Market cap$239.2B
Cash & investments$13.19Bas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-03

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 Apremilast
Plaque Psoriasis · NCT06088199
August 2026
Primary data collected
Phase 3 Dazodalibep
Sjogren's Syndrome · NCT06104124
July 2026
Primary data collected
Phase 1/2 sotorasib
KRAS p.G12C Mutant Advanced Solid Tumors · NCT03600883
May 2026
Primary data collected

Upcoming readouts

Phase 3 ABP 234
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) · NCT06430866
December 2026
Ongoing
Phase 1/2 AMG 732
Thyroid Eye Disease · NCT06401044
January 2027
Ongoing
Phase 3 Maridebart Cafraglutide
Obesity · NCT06858839
January 2027
Ongoing
Phase 3 Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight · NCT06858878
January 2027
Ongoing
Phase 2 Inebilizumab
Neuromyelitis Optica Spectrum Disorder · NCT05549258
April 2027
Recruiting
Phase 3 Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS) · NCT06700343
April 2027
Ongoing
Phase 3 Maridebart cafraglutide
Obesity Disease · NCT06987695
April 2027
Ongoing

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 1/2 Anvumetostat
Advanced MTAP-null Solid Tumors · NCT05094336
November 2026
Ongoing

Cash position

Amgen Inc. reported $13.19B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $3.86B for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow AMGN, you can start the conversation.
Track AMGN in real time
See live implied volatility for AMGN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on AMGN
Contact — questions or corrections about AMGN: dukeupt@gmail.com